Abstract:The enzyme complex IB kinase (IKK) is an essential activator of NF-B signaling pathway involved in propagating the cellular response to inflammation. The complex contains two functional subunits IKK and IKK, which are structurally conserved kinases and selective inhibition of them would result in distinct biological effects. However, most existing IKK inhibitors show moderate or high promiscuity for the two homologous kinases. Understanding of the molecular mechanism and biological implication underlying the specific interactions in IKK-ligand recognition is thus fundamentally important for the rational design of selective IKK inhibitors. In the current work, we integrated molecular docking, quantum mechanics/molecular mechanics calculation and Poisson-Boltzmann/surface area analysis to investigate the structural basis and energetic property of the selective binding of small-molecule ligands to IKK and IKK. It was found that the selectivity is primarily determined by the size and topology difference in ATP-binding pocket of IKK and IKK kinase domains; bulky inhibitor molecules commonly have, respectively, low and appropriate affinities towards IKK and IKK, and thus exhibit relatively high selectivity for IKK over IKK, whereas small ligands can only bind weakly to both the two kinases with low selectivity. In addition, the conformation, arrangement and distribution of residues in IKK pockets are also responsible for constituting the exquisite specificity of ligand binding to KK and IKK. Next, a novel quantitative structure-selectivity relationship model was developed to characterize the relative contribution of each kinase residue to inhibitor selectivity and to predict the selectivity and specificity for a number of known IKK inhibitors. Results showed that the active-site residues contribute significantly to the selectivity by directly interacting with inhibitor ligands, while those protein portions far away from the kinase active sites may also play an important role in determining the selectivity through long-range non-bonded forces and indirect allosteric effect.

The "sneaking-ligand" approach: cell-type specific inhibition of the classical NF-κB pathway

Intercellular delivery of NF-κB inhibitor peptide utilizing small extracellular vesicles for the application of anti-inflammatory therapy

Cellular Delivery of Functional Peptides to Block Cytokine Gene Expression

High-throughput screening and in vitro evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-talk

Mechanisms of NF-κB p65 and strategies for therapeutic manipulation

NF-κB is a Negative Regulator of IL-1β Secretion As Revealed by Genetic and Pharmacological Inhibition of IKKβ

Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides

NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta

Rapid TNFR1-dependent Lymphocyte Depletion in Vivo with a Selective Chemical Inhibitor of IKKβ

The small-molecule inhibitor selectivity between IKKα and IKKβ kinases in NF-κB signaling pathway.

Development of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling

Small Molecule NF-κB Pathway Inhibitors in Clinic

Decreasing Cell Adhesion Between Endothelial Cells to T Cells Through Inhibition of NF-κB Activity

Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling

Identification and study of new NF‐κB‐inducing kinase ligands derived from the imidazolone scaffold

[Establishment of a Cell Model Targeted to NFAT Signal Transduction Pathway for Preliminary Screening of FK506-like Immunosuppressants].

Inhibition of IL-1β release from macrophages targeted with necrosulfonamide-loaded porous nanoparticles

An inhibitor of the interaction between the transcription factor NRF2 and the E3 ligase adapter β-TrCP suppresses lipopolysaccharide- mediated inflammation.

Targeted and Activatable Nanosystem for Fluorescent and Optoacoustic Imaging of Immune-Mediated Inflammatory Diseases and Therapy Via Inhibiting NF-κB/NLRP3 Pathways

Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κB

Design and Synthesis of Novel Aminoindazole-pyrrolo[2,3- b]pyridine Inhibitors of IKKα That Selectively Perturb Cellular Non-Canonical NF-κB Signalling